卵巢癌中错配修复缺陷的高度同质性
研究对582例卵巢癌进行组织芯片免疫组化筛查,478例可判读中10例疑似错配修复缺陷,经大切片免疫组化与PCR验证9例确认为MMR缺陷/MSI。MMR缺陷/MSI主要见于子宫内膜样癌(8/35,23%),也见于1例浆液性癌(1/358,0.3%),在黏液性、透明细胞、癌肉瘤及混合癌中未见到。所有可获得的含癌组织块(n=114)免疫染色显示MMR状态在整个瘤块中均匀一致。
要点
- 卵巢子宫内膜样癌中MMR缺陷/MSI占23%(8/35),其他亚型少见。
- MMR缺陷/MSI通常累及整个肿瘤组织,提示MMR失活发生于肿瘤发生早期。
- 组织芯片筛查后需大切片免疫组化联合PCR验证MMR缺陷/MSI。
核心结论
- MSI存在于相当比例的卵巢子宫内膜样癌中,也可发生于其他亚型。
- MMR缺陷/MSI通常累及整个肿瘤组织,提示MMR失活在部分卵巢癌中发生于肿瘤发生早期。
研究设计与样本
- 对N=582例卵巢癌进行组织芯片免疫组化筛查MMR缺陷,478例可判读。
- 10例疑似MMR缺陷者经大切片重复免疫组化联合PCR-based MSI分析验证,9例确认。
主要发现
- MMR缺陷/MSI见于8/35(23%)子宫内膜样癌和1/358(0.3%)浆液性癌。
- 34例黏液性癌、23例透明细胞癌、17例恶性混合苗勒管瘤(癌肉瘤)及11例混合癌中未见MMR缺陷/MSI。
- MMR缺陷涉及PMS2/MLH1蛋白缺失6例,MSH2和/或MSH6缺失3例。
- 7例MMR缺陷癌为MSI-high(均为子宫内膜样),1例为MSI-low(子宫内膜样),1例明确MMR蛋白缺失的浆液性癌表现为微卫星稳定。
- 5例MLH1蛋白缺失的子宫内膜样癌中4例观察到MLH1启动子甲基化。
临床怎么用
- 卵巢子宫内膜样癌应考虑MMR/MSI检测以识别可能受益于免疫检查点抑制剂的患者。
- 组织芯片筛查疑似MMR缺陷后,应经大切片免疫组化联合PCR验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mismatch repair (MMR) deficiency and Bethesda panel microsatellite instability (MSI) are increasingly analyzed to identify tumors that might benefit from immune checkpoint inhibitors, but tumor heterogeneity is a potential obstacle for such analyses. In ovarian cancer, data on intratumoral heterogeneity of MMR deficiency/MSI are lacking. METHODS: N = 582 ovarian cancers were screened for MMR deficiency by immunohistochemistry (IHC) on a tissue microarray. 10 cases suspect for MMR deficiency were identified among 478 interpretable cancers and repeated IHC on large sections combined with polymerase chain reaction (PCR)-based MSI analysis validated MMR deficiency/MSI in 9 of these tumors. RESULTS: MMR deficiency/MSI was predominantly seen in endmetrioid cancers (8 of 35, 23%) and also in 1 of 358 serous carcinomas (0.3%), but was absent in 34 mucinous carcinomas, 23 clear cell carcinomas, 17 malignant mixed Mullerian tumors (carcinosarcomas), and 11 mixed carcinomas. MMR deficiency involed protein loss of PMS2/MLH1 in 6 cases and of MSH2 and/or MSH6 in 3 cases. 7 MMR deficient cancers were MSI-high (all endometrioid), one was MSI-low (endometrioid) and one cancer with unequivocal MMR protein loss exhibited microsatellite stability (serous). MLH1 promotor methylation was observed in 4 of 5 endometrioid cancers with MLH1 protein loss. Immunostaining of all available cancer-containing tissue blocks (n = 114) of tumors with confirmed MMR deficiency/MSI revealed uniform MMR status throughout the entire tumor mass. CONCLUSIONS: Our data show that MSI is present in a substantial proportion of endometrioid ovarian cancers but can also occur in other tumor subtypes. MMR deficiency/MSI typically involves the entire tumor mass, suggesting that MMR inactivation occurs early in tumorigenesis in a subset of ovarian cancers.
引用
- Fraune C, Rosebrock J, Simon R, et al. High homogeneity of MMR deficiency in ovarian cancer. Gynecol Oncol. 2020. PMID: 31924330. doi:10.1016/j.ygyno.2019.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。